The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against solid tumors and infectious diseases, announced today that the U.S. Patent and ...

4D-150 continues to be well tolerated during up to three years of follow-up in all patients (n=71) treated with 3E10 vg/eye dose, with the highest 4D-150-related intraocular inflammation (SUN/NEI ...

Allegro MicroSystems, Inc. ( NASDAQ: ALGM) Q4 2025 Earnings Call May 8, 2025 8:30 AM ET Jalene Hoover - Investor Relations Mike Duke - President and Chief Executive Officer Derek D’Antilio - Chief ...

Net Loss: For the first quarter of 2025, the Company generated a net loss attributable to its shareholders of $19.6 million, ...

Provides ReciBioPharm's customers with access to NewBiologix's Xcell-Eng-HEK293 cell lines for advanced therapies <l ...

To manage The Surprised, Mr. Charran recommends combining structured updates with documented communication. “Talk it out.

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsCarrie Gillard - Director, IRHarley Finkelstein ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit ...

Whether it’s reducing workloads, responding more efficiently to internal client needs, or informing decisions with data, Insight+ helps corporate legal teams stay ahead of the curve in today’s ...